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Background: Checkpoint kinase1 (CHK1), which is a key component of DNA-damage-activated checkpoint signalling response,
may have a role in breast cancer (BC) pathogenesis and influence response to chemotherapy. This study investigated the
clinicopathological significance of phosphorylated CHK1 (pCHK1) protein in BC.
Method: pCHK1 protein expression was assessed using immunohistochemistry in a large, well-characterized annotated series of
early-stage primary operable invasive BC prepared as tissue microarray (n¼ 1200).
Result: pCHK1 showed nuclear and/or cytoplasmic expression. Tumours with nuclear expression showed positive associations
with favourable prognostic features such as lower grade, lower mitotic activity, expression of hormone receptor and lack of
expression of KI67 and PI3K (Po0.001). On the other hand, cytoplasmic expression was associated with features of poor prognosis
such as higher grade, triple-negative phenotype and expression of KI67, p53, AKT and PI3K. pCHK1 expression showed an
association with DNA damage response (ATM, RAD51, BRCA1, KU70/KU80, DNA-PKCa and BARD1) and sumoylation (UBC9 and
PIASg) biomarkers. Subcellular localisation of pCHK1 was associated with the expression of the nuclear transport protein KPNA2.
Positive nuclear expression predicted better survival outcome in patients who did not receive chemotherapy in the whole series
and in ER-positive tumours. In ER-negative and triple-negative subgroups, nuclear pCHK1 predicted shorter survival in patients
who received cyclophosphamide, methotrexate and 5-florouracil chemotherapy.
Conclusions: Our data suggest that pCHK1 may have prognostic and predictive significance in BC. Subcellular localisation of
pCHK1 protein is related to its function.
Systemic therapy targeted at disrupting DNA damage response
(DDR) in solid tumours is attracting attention and it is likely to
expand in the coming years. A complex series of checkpoint
pathways are recognised to have important roles in the repair of
any DNA damage (Niida and Nakanishi, 2006). This mechanism is
mediated through an array of DDR proteins that when activated
are involved in arrest of cell cycle to allow DNA repair process to
proceed, thus preventing DNA replication and mitosis in the
presence of unrepaired damage; otherwise apoptosis or mutagen-
esis will occur (Bartek and Lukas, 2003; Dai and Grant, 2010).
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Following DNA damage, sensor multiprotein complexes activate
proximal transducers (that is ATM, ATR), which in turn
phosphorylate/activate the distal transducers including serine/
threonine kinase Checkpoint Kinase 1 (CHK1; Walworth et al,
1993; Sanchez et al, 1997; Kaneko et al, 1999; Tse et al, 2007; Zaugg
et al, 2007; Dai and Grant, 2010). Phosphorylated CHK1 (pCHK1)
is released to activate the effectors (that is, CDC25) causing their
sequestration, degradation or phosphorylation. These combined
effects will halt the progression of cell cycle at different phases and
are referred to as mobile messenger kinases (Kastan and Bartek,
2004; Kramer et al, 2004; Dai and Grant, 2010).
Protein phosphorylation is a well-characterised biochemical
process for the reversible regulation of protein activity. In response
to DNA damage or replication stress, CHK1 becomes phosphory-
lated at several C-terminal residues, including the highly conserved
S345 and S317 sites (Wilsker et al, 2008; Tapia-Alveal et al, 2009)
and this phosphorylation regulates CHK1 intracellular location
(Kramer et al, 2004; Loffler et al, 2007; Wilsker et al, 2008). CHK1
appears to function in a cell cycle-dependent manner during at
least two phases of the unperturbed cell cycle: S phase and mitosis
(Wilsker et al, 2008).
Previous studies have demonstrated that activated CHK1 and
CHK2 phosphorylate a plethora of effectors involved in check-
points including: effectors that can lead to cell cycle delay (Cdc25A,
Cdc25B and p53; Peng et al, 1997; Hirao et al, 2000; Zhao and
Piwnica-Worms, 2001), DNA repair (BRCA1 and Rad51; Yarden
et al, 2002; Sørensen et al, 2005), induction of apoptosis if the
damage is irreparable (p53 and E2F1; Ahn et al, 2004) and
chromatin remodelling (Tousled like kinase1/2; Groth et al, 2003).
DDR checkpoints can be classified generally into two parallel
pathways that respond to diverse types of DNA-damaging agents.
In the ATM/ATR-CHK1/CHK2-Cdc5s pathway (for reversible and
fast response to DNA damage) CHK 1 is regarded as the key distal
transducer. The second pathway is the p53-dependent pathway
(for irreversible and slower response). In this pathway CHK1/
CHK2, with ATM/ATR, phosphorylates p53 or Mdm2 to promote
p53 stabilisation (Zhou and Bartek, 2004; Dai and Grant, 2010).
Cancer cells use intact DNA repair mechanisms to evade DNA
damage induced by chemotherapy or radiotherapy. Therefore, it
was hypothesised that using agents that target DDR proteins
including checkpoint kinases can enhance the effect of chemother-
apy and radiotherapy and decrease resistance of cancer cells to this
treatment modality (Verlinden et al, 2007). This approach is
expected to be more effective in certain subtypes of cancer
such as p53-deficient tumours. In normal cells, p53 induces G1
arrest in response to DNA damage, whereas tumour cells that are
often p53-deficient are defective in G1 arrest; therefore, cancer
cells, unlike normal cells, rely mainly on S or G2 checkpoints
that are mediated by CHK1 (Chen et al, 2006). Currently, CHK1
represents one of the most attractive and potential target for
anticancer drug development directed against the DDR network
(Dai and Grant, 2010).
The aim of the current study was to investigate the clinical
and biological significance of pCHK1 protein expression in BC
with particular attention to its role in DDR and response to
chemotherapy.
MATERIALS AND METHODS
The current study was conducted using a consecutive series of 1200
primary operable stage I–III invasive BC that were prepared as a
tissue microarray (TMA) from formalin-fixed, paraffin-embedded
tissue specimens of patients presented to Nottingham Breast Unit
between 1988 and 1998. The age of the patients was less than 70
with a median of 55 years (range 18–70) with a tumour size of less
than 5 cm in diameter.
Clinical and pathological data as well as data on a wide range of
biomarkers oestrogen receptor (ER)-related genes (ER, progester-
one (PgR) and androgen (AR) receptor, GATA3, FOXA1), HER
family members (HER1, HER2, HER3 and HER4), DDR proteins
(RAD51, BRCA1, BARD1, DNA-PKCa, KU70/KU80, UBC9 and
ATM), basal (CK5 and CK17) and luminal (CK18) cytokeratin,
nuclear transport protein importin subunit alpha-2 (KPNA2; clone
Ab84440, Abcam Ltd, Cambridge, UK) used in dilution of 1 : 400
with 60-min incubation; Alshareeda et al, 2014), proliferation and
cell cycle-associated proteins (KI67 and p53) and PI3K/AKT
pathway proteins (PI3K and AKT) were available. The immunor-
eactivity, scoring and the optimal cutoff points for these markers
were defined as described in the previous studies (Rakha et al,
2006, 2009; Aleskandarany et al, 2011, 2012; Alshareeda et al, 2012,
2013; Agboola et al, 2014).
Data related to outcome including locoregional recurrence,
distant metastasis and mortality were collected prospectively.
Breast cancer (BC)-specific survival (BCSS) is defined as the time
interval in months from the date of the primary surgery until death
occurrence due to BC with a median of 129 months (range 4–243
months). Distant metastasis-free survival is defined as duration in
months from the primary surgery to the development of distant
metastasis with a median of 114 months (range 5–241 months).
Patients were managed according to a uniform protocol based on
the Nottingham Prognostic Index (NPI) groups, ER and the
menopausal status. Patients were offered adjuvant systemic therapy
if NPI was 43.4. If NPI was 43.4 and ER-positive, endocrine
therapy in form of tamoxifen was given, and if the patient was
premenopausal Zoladex was added to the previous protocol. A
systemic chemotherapy regimen of cyclophosphamide, methotrex-
ate and 5-florouracil (CMF) was used if the patient was ER-
negative, provided that the patient was considered fit enough to
withstand this regimen. In this series, 25% received chemotherapy
and 45% received hormone therapy. None of the patients received
anti-HER2-targeted therapy or neoadjuvant therapy.
Immunohistochemistry method. The expression of pCHK1 was
investigated in breast tumours using TMA prepared using 0.6-mm
cores. Freshly cut 4-mm sections of the TMA were stained using
pCHK1 antibody (CHK1phospho-S345; AbCam clone Ab 58567),
which is the commonly used biomarker of Chk1 activation
(Wilsker et al, 2008). At first, the slides were heated on a hot
plate to 60 1C for 10min and then deparaffinised in xylene twice
for 5min each. The slides were rehydrated in descending alcohol
concentrations and then in water for 5min. Antigen retrieval was
performed by incubating slides in retrieval solution of citrate
buffer, pH 6, for 20min using a microwave. The slides were cooled
in cold tap water for 5min. The immunohistochemical staining
was performed using Novocastra Novolink polymer detection kit
system (Leica Microsystem, Newcastle, UK) according to the
manufacturer’s instructions. Briefly, hydrogen peroxide was added
to block the endogenous peroxidase activity to decrease unwanted
background staining. The primary antibody was added at optimum
dilution (1 : 150) and incubated for 1 h. After washing the slides,
the polymer link was incubated for 30min. DAB was added for
5min. Haematoxylin was used as a counterstain for 5min followed
by rinsing in tap water. Finally, the slides were dehydrated in
alcohol, cleared in xylene and then cover-slipped using DPX (BDH,
Poole, UK).
Scoring of CHK1 in TMA core slides. Assessment of pCHK1
expression was conducted using a web-based interface (Distiller,
Slide path Ltd, Dublin, Ireland) after high-resolution digital-image
virtual slides of the stained TMA slides were prepared at  20
magnification using NanoZoomer (Hamamatsu Photonics,
Welwyn Garden City, UK). The scoring method was semiquantitative
using a modified histochemical score (H-score) that includes both
the percentage of the stained cells and the staining intensity.
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The intensity of staining was scored on a scale of 0–3, where the (0)
was referred to negative, (1) referred to weak, whereas the
moderate cases were scored as (2) and the strong were scored as
(3). Visual estimation was used to determine the percentage of
positive cells. The final score is achieved by multiplication of 2
indices and the results range from 0 to 300. Records of pCHK1
expression pattern were visually estimated as nuclear, cytoplasmic
or combined nuclear and cytoplasmic staining. The scoring was
carried on without previous knowledge of clinical data. Cores with
invasive tumours less than 15% were excluded.
Statistical analysis. Statistical analysis was performed by using the
SPSS IBM 21 statistical software (IBM, New York, NY). The
relationship between pCHK1 and different clinicopathological
variables was assessed using w2-test for categorical data and Mann–
Whitney U-test for continuous variables. Survival curves were
obtained using Kaplan–Meier method for outcome estimation and
significance determined using the log-rank test. Multivariate
survival analysis was performed using Cox hazard regression
model including established prognostic variables significant on
univariate analysis. Two-tailed P-value less than 0.01 was
considered significant in view of multiple comparisons.
RESULTS
Of the whole series, 1079 (90%) cases had sufficient cores to
perform scoring. The expression of pCHK1 was detected in the
nuclei and cytoplasm of the neoplastic cells (Figure 1). Nuclear
pCHK1 expression was detected in 50% of cases (40%) and had a
median H-score of 29 (range 0–300), whereas cytoplasmic pCHK1
was detected in 94% (40%) and had a median H-score of 200
(range 0–300). There was a correlation between nuclear and
cytoplasmic expression (Po0.0001). For statistical analysis,
expression was dichotomised using cutoff points that were selected
based on histogram distribution and by the X-tile computer
software analysis (Camp et al, 2004) that dichotomises marker
expression according to association with outcome. The cutoff
points were selected as follows: for nuclear pCHK1, an H-score of
20 with 791 out of 1079 (73%) of the cases showing negative/low
nuclear expression and for cytoplasmic pCHK1 expression H-score
of 80 was used with 128 out of 1079 (12%) of the cases showing
negative/low expression.
Association with clinicopathological parameters. Higher nuclear
pCHK1 immunohistochemical expression was associated with
markers of good prognosis including lower grade with a low
proliferation status, smaller size, good NPI and expression of
oestrogen receptor-related proteins (ER, PgR, AR, GATA3 and
FOXA1). Negative association was seen with triple-negative
phenotype and tumours expressing high ki67-labelling index
(Ki67LI) and PI3K (Po0.0001). Conversely, cytoplasmic pCHK1
was associated with higher grade with a high proliferation status,
poor NPI and lack of expression of ER and PgR. There was a
positive association between cytoplasmic expression and triple-
negative phenotype, Ki67LI and p53, CK5, AKT and PI3K
expression (Tables 1 and 2).
Strong correlation was observed between pCHK1 expression
with other DDR proteins. There was a positive association between
nuclear pCHK1 and expression of homologous recombination
(ATM, RAD51 and BRCA1) and sumoylation (PIASg and nuclear
UBC9) markers. Negative association of borderline significance
(P¼ 0.037) was identified with ATR. Cytoplasmic pCHK1
expression was positively associated with the expression of
nonhomologous end-joining markers (KU70/KU80, PIASg,
DNA-PKCa and cytoplasmic UBC9) and with the cytoplasmic
homologous recombination marker BARD1 (Table 2).
Regarding subcellular localisation of pCHK1, there was an
association between the nuclear transport protein KPNA2
and cytoplasmic/nuclear expression pCHK1. Positive KPNA2
expression was associated with cytoplasmic localisation of the
pCHK1 with reduced/negative nuclear expression (nuclear-negative/
cytoplasmic-positive phenotype), whereas absence of KPNA2 protein
was associated with the lack of cytoplasmic pCHK1 localisation
(cytoplasmic negative/nuclear-positive or -negative phenotypes
(Table 3).
Relationship with clinical outcome. In the whole series, high
expression of nuclear pCHK1 showed an association of borderline
significance with longer BCSS (P¼ 0.018 at 5 years and P¼ 0.030
at 15 years of survival). Conversely, high expression of cytoplasmic
pCHK1 was associated with shorter BCSS (P¼ 0.009 at 5 years and
P¼ 0.024 at 15 years of survival) as shown in Figure 2. However,
multivariate Cox regression analysis including potential confound-
ing factors of (tumour size, grade, stage, ER and therapy) showed
that neither nuclear nor cytoplasmic pCHK1 expression were
independent predictors of BCSS (P¼ 0.551 and P¼ 0.344,
respectively). Association with distant metastasis-free interval was
not significant (P¼ 0.221 and P¼ 0.324 for nuclear and cyto-
plasmic pCHK1, respectively); the data are not shown.
When the cohort was stratified with respect to chemotherapy, a
significant association between positive nuclear pCHK1 expression
and longer BCSS was found in the subgroup of patients who did
not receive chemotherapy (P¼ 0.014), whereas for those receiving
chemotherapy there was no statistical difference (P¼ 0.351;
Figure 3). Further stratification according to the ER status revealed
that similar associations were maintained in the ER-positive
subgroup with an association between nuclear pCHK1 expression
and longer BCSS in chemotherapy-naive patients (w2¼ 10.1,
P¼ 0.001) and no association in chemotherapy-treated patients.
Interestingly, in the ER-negative subgroup, the opposite was
identified; no association with outcome was observed in
chemotherapy-naive patients, whereas among the patients who
received chemotherapy longer BCSS was seen in those whose
tumours lacked nuclear pCHK1 (w2¼ 5.4, P¼ 0.021). When triple-
negative tumours were selected, an association between the lack of
nuclear pCHK1 and better outcome in chemotherapy-treated
subgroup was also obtained (P¼ 0.043; Figure 4).
P-interaction between pCHK1 and chemotherapy was positive
in the whole series (P¼ 0.012 (HR¼ 2.4 and 95%CI¼ 1.2–4.7)).
When stratified according to ER, P-interaction was significant in
the ER-negative subgroup (P¼ 0.026 (HR¼ 2.8 and 95% CI¼ 1.1–
7.1)) but not in the ER-positive subgroup (P¼ 0.226).
Regarding cytoplasmic CHK1, lack of expression showed
borderline significance with better BCSS in patients who did not
receive chemotherapy (P¼ 0.027) but not in those who received
chemotherapy (P¼ 0.816; Figure 3).
DISCUSSION
DNA damage is a ubiquitous process, occurring in all nucleated
normal cells and, to a higher degree, in neoplastic cells. Sensing of
DNA damage is mediated through several distinct complexes of
proteins, which are determined by the nature of the DNA lesions
and act to catalyse repair (Dai and Grant, 2010). Formation of
repair complexes initiates signalling processes that lead to cell cycle
arrest to allow DNA repair without the occurrence of additional
DNA replication or cell division. CHK1 is an important protein
involved in cell cycle control during DDR and is proposed to be a
potential marker that can influence the response of proliferating
tumour cells to chemotherapies that damage DNA. In addition,
CHK1 inhibitors have emerged as promising novel therapeutic
agents (Thompson and Eastman, 2013).
Role of CHK1 in breast cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.576 903
This study aimed to investigate pCHK1 protein expression in
BC to further understand its role in DDR and whether it is
associated with tumour chemotherapy response and therefore
could influence patients’ outcome. The expression of pCHK1 was
detected in the nucleus and/or in the cytoplasm of the malignant
cells. This different subcellular localisation correlated differently
with clinicopathological parameters and patients’ outcome. Our
results demonstrate that the tumours expressing nuclear pCHK1
feature variables associated with good prognosis including lower
grade, lower proliferation status and positivity for hormone
receptors. In addition, they express other processes involved in
DNA-damage-sensing and homologous recombination DNA-
damage repair mechanisms (ATM, RAD51 and BRCA1) and
related sumoylation proteins (UBC9 and PIASg). Downregulation
Figure 1. Immunohistochemical expression of CHK1 at  20. CHK1 immunostaining for both nuclear and cytoplasmic in A–C ,whereas in D there
is weak cytoplasmic staining; the inset refers to the high power. Panel E demonstrates only nuclear pCHK1 expression, whereas exclusive
cytoplasmic pCHK1 expression appears in F.
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of pCHK1 expression was seen more frequently in tumours with
high proliferation status, positive for PI3K and HER2 and in those
showing triple-negative phenotype. In contrast, cytoplasmic
expression is associated with variables characteristic of poor
prognosis including higher grade, high proliferation status, lack
of hormone receptors and triple-negative phenotype. Cytoplasmic
pCHK1 was associated with non-homologous end-joining markers
(KU70/KU80 and DNA-PKCa) and with cytoplasmic expression of
the homologous recombination (BARD1) and the related sumoyla-
tion (UBC9) proteins. Combinatorial expression of nuclear and
cytoplasmic expression of pCHK1 revealed that association with
good prognostic variables and DDR markers was positive in pure
nuclear expression, intermediate in double-negative cases and
negative in cases with pure cytoplasmic expression (data not
shown). These results may indicate that the cytoplasmic CHK1
protein in BC tissue is not just a form of an aberrant/nonfunctional
protein but a protein that may have a function contrasting with
that of the functionally normal nuclear localisation of the pCHK1
protein (Wang et al, 2012).
Using immunoblotting and subcellular fractionation techniques,
Niida et al (2007) have detected CHK1 in both the cytoplasm and
the nucleus at almost the same level, although its expression is
decreased in the cytoplasm in the late S phase. They have found
that pCHK1 at S317 is predominantly cytoplasmic in the early S
phase and nuclear in the late S phase, whereas the expression of
CHK1 phosphorylated at S345 is detected only in the cytoplasmic
fraction. The findings of these authors and others (Wilsker et al,
2008) indicate that not only phosphorylation status but also
phosphorylation site can affect subcellular localisation of CHK1.
Niida et al (2007) suggested that pCHK1 at S345, but not at S317,
might be important for cytoplasmic localisation of Chk1 during the
S phase and that the mobility shift in CHK1, upon DNA damage,
was observed only in the cytoplasm and the phosphorylation is
critical for signal transducing to downstream target. In fission yeast
it was reported that phosphorylation of CHK1 at ser345 appears to
be required for checkpoint function, and this phosphorylation
increases the pCHK1 in the nucleus through interaction with 14-3-
3 protein (Dunaway et al, 2005). It was also hypothesised that the
cytoplasmic expression of CHK1 may have a role in tumorigenesis
through the DNA damage sensors and as a transducer for signal
pathway, and take this action as a pathway for tumour survival
(Bartek and Lukas, 2003; Harper and Elledge, 2007); however,
further studies are needed to confirm this hypothesis.
The subcellular localisation of CHK1 and the association
between aggressive behaviour of cytoplasmic CHK1 in this study
may be explained by a defective function of CHK1 in BC. Puc et al
(2005) used a mouse mammary tumour model to study the effect
of cytoplasmic CHK1 on genomic instability. They revealed that, at
the G2 phase of the cell cycle, CHK1 observed to leave from the
nucleus at the time of AKT kinase phosphorylation peak and the
reduction of nuclear CHK1 could be explained by the raise of
Cdc25A protein noticed in the G2/M phase (Bernardi et al, 2000).
Table 1. Association between nuclear and cytoplasmic CHK1 expression and clinicopathological parameters
Nuclear expression Cytoplasmic expression
Clinicopathological variables Neg./low (%; o20) High (%X20) P-value Neg./low (%; o80) High (%; X80) P-value
Age
o50 263 (33) 95 (33) 41 (32) 317 (33)
X50 528 (67) 193 (67) 0.935 87 (68) 633 (67) 0.763
Menopause
Pre 288 (37) 112 (39) 45 (35) 355 (37)
Post 502 (63) 176 (61) 0.464 83 (65) 594 (63) 0.621
Size
o1.5 cm 369 (47) 157 (55) 66 (52) 460 (49)
41.5 cm 417 (53) 131 (45) 0.028 61 (48) 486 (51) 0.479
Lymph node stage
1 414 (58) 156 (64) 67 (62) 502 (59)
2 244 (34) 75 (31) 0.221 34 (31) 285 (34) 0.858
3 54 (8) 13 (5) 7 (7) 60 (7)
Grade
1 95 (12) 73 (26) 26 (20) 142 (15)
2 255 (33) 107 (37) o0.0001 61 (48) 301 (32) o0.0001
3 434 (55) 107 (37) 40 (32) 500 (53)
Mitotic count
1 226 (30) 120 (44) 61 (50) 285 (31)
2 149 (20) 58 (20) o0.0001 21 (17) 186 (21) o0.0001
3 384 (51) 98 (36) 41 (33) 440 (48)
Stage
1 456 (58) 189 (66) 84 (65) 560 (59)
2 256 (33) 79 (28) 0.061 34 (27) 301 (32) 0.393
3 73 (9) 19 (6) 10 (8) 82 (9)
NPI
Good 194 (26) 121 (45) 50 (42) 265 (30)
Moderate 432 (58) 121 (45) o0.0001 54 (46) 498 (55) 0.016
Poor 123 (16) 29 (10) 14 (12) 138 (15)
LVI
Negative 505 (64) 196 (68) 0.237 85 (67) 615 (65) 0.703
Positive 279 (36) 91 (32) 42 (33) 328 (35)
Abbreviations: CHK1¼ checkpoint kinase1; LVI¼ lymphovascular invasion; Neg¼ negative; NPI¼Nottingham prognostic index. Bold indicates significant P-value (o0.05).
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Table 2. Associations between CHK1 and different proteins
Nuclear CHK1 expression Cytoplasmic CHK1 expression
Biomarkers
Neg./low
expression
no. (%)
High expression
no. (%) P-value
Neg./low expression
no. (%)
Positive expression
no. (%) P-value
Oestrogen receptor (ER)-related proteins
ER
NEG 230 (29) 45 (16) o0.0001 14 (11) 266 (28) o0.0001
POS 556 (71) 241 (84) 114 (89) 683 (72)
PgR
NEG 346 (45) 86 (31) o0.0001 36 (29) 395 (43) 0.002
POS 426 (55) 190 (9) 90 (71) 526 (57)
AR
NEG 287 (40) 72 (28) o0.0001 35 (31) 323 (38) 0.149
POS 424 (60) 186 (72) 79 (69) 531 (62)
GATA3
NEG 389 (72) 80 (49) o0.0001 63 (76) 405 (65) 0.057
POS 151 (28) 83 (51) 20 (24) 214 (35)
FOXA1
NEG 373 (68) 68 (35) o0.0001 34 (38) 407 (63) o0.0001
POS 174 (32) 125 (65) 55 (62) 243 (37)
HER family proteins
HER2
NEG 658 (86) 254 (91) 0.032 111 (90) 800 (87) 0.256
POS 110 (14) 26 (9) 12 (10) 124 (13)
HER1 (EGFR)
NEG 1620 (80) 230 (81) 0.544 106 (84) 744 (80) 0.229
POS 159 (20) 53 (19) 20 (16) 191 (20)
HER3
NEG 44 (6) 37 (14) o0.0001 12 (11) 69 (8) 0.289
POS 685 (94) 222 (86) 99 (89) 807 (92)
HER4
NEG 75 (10) 53 (19) o0.0001 26 (22) 102 (11) 0.001
POS 696 (90) 225 (81) 95 (79) 825 (89)
Triple-negative (TN)
Non-TN 614 (79) 251 (90) o0.0001 115 (90) 750 (81) 0.009
TN 160 (21) 28 (10) 12 (10) 175 (19)
DNA repair proteins
ATM
NEG 397 (61) 104 (44) o0.0001 45 (57) 455 (65) 0.865
POS 257 (39) 135 (56) 34 (43) 358 (44)
ATR
NEG 267 (8) 110 (67) 0.037 45 (85) 332 (61) 0.719
POS 195 (42) 54 (33) 32 (42) 216 (39)
RAD51 (nuclear)
NEG 426 (63) 65 (46) 0.001 44 (68) 267 (57) 0.107
POS 147 (37) 75 (54) 21 (32) 200 (43)
BRCA1
NEG 128 (20) 26 (12) 0.005 16 (17) 138 (18) 0.757
POS 513 (80) 199 (88) 80 (83) 631 (82)
BARD1 (cytoplasmic)
NEG 64 (12) 23 (12) 0.896 22 (28) 65 (10) o0.0001
POS 475 (80) 162 (88) 58 (72) 578 (90)
PIASc
NEG 212 (25) 47 (16) 0.002 43 (36) 216 (21) o0.0001
POS 641 (75) 245 (84) 75 (64) 810 (79)
KU70/KU80
NEG 113 (13) 41 (14) 0.690 40 (33) 114 (11) o0.0001
POS 766 (87) 254 (86) 83 (67) 936 (99)
DNA-PKCa
NEG 100 (15) 29 (13) 0.581 26 (33) 103 (13) o0.0001
POS 553 (85) 186 (87) 53 (67) 685 (87)
UBC9 nuclear
NEG 387 (55) 97 (42) o0.0001 50 (58) 434 (51) 0.258
POS 312 (45) 136 (58) 36 (42) 411 (49)
UBC9 cytoplasmic
NEG 373 (36) 66 (38) 0.662 51 (58) 288 (34) o0.0001
POS 486 (64) 108 (62) 35 (42) 558 (66)
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Another possible explanation is that sequestration of cytoplasmic
pCHK1 occurs in genomically unstable cells such as PTEN-
deficient cells. Puc et al (2005) have provided evidence that
primary BC cells lacking PTEN expression have increased AKT
phosphorylation, elevated cytoplasmic CHK1, reduced nuclear
location and structural and numerical chromosomal alterations.
Therefore, this accumulated cytoplasmic CHK1 occurs in geneti-
cally unstable cells that lack an essential tumour suppressor gene
(Shen et al, 2007; Yin and Shen, 2008) that protects the genome
stability, hence it is associated with aggressive behaviour tumours,
whereas the nuclear type usually occurs in genetically stable cells.
In addition, activation of CHK1 occurs in the nucleus; therefore,
this nuclear accumulation seems to be of a great importance in the
preparation for functional DDR (Goto et al, 2012).
Interestingly, the association between subcellular localisation of
CHK1 and the nuclear transport protein KPNA2 may indicate an
active process and not just sequestration of an aberrant protein
into the cytoplasm. However, these observations are best
interpreted when considering the in vitro functional studies of
the CHK1 protein (see below).
Several studies have investigated CHK1 in BC cell lines, but only
a few have investigated CHK1 protein expression in human breast
carcinoma. Most of the previous studies used the total CHK1
protein and not the phosphorylated forms. Verlinden et al (2007)
showed that CHK1 expression was higher in high-grade triple-
negative cases. High CHK1 transcript level was associated with
tumours of large size, high histological grade and low/absent ER
and PgR; however, they did not find a significant association with
HER2 or lymph node metastasis. Other authors have demonstrated
that high CHK1 expression was positively associated with high-
grade and high ki67 level, positive lymph nodes and large tumour
size and have regarded CHK1 as a marker of aggressiveness
(Lundgren et al, 2008). However, most of the studies of CHK1
expression in human BC did not consider the phosphorylated form
or subcellular localisation of this protein. The exact molecular
mechanism that mediates subcellular localisation of the CHK1
protein in BC remains unclear. Some authors suggest that there is
continuous shuttling of CHK1 occurring both under normal
growth condition (Enomoto et al, 2009; Goto et al, 2012; Xu et al,
2012) and in response to DNA damage (Dunaway et al, 2005;
Zhang et al, 2005; Smits et al, 2006). Under normal growth
conditions, CHK1 expression is mainly located in the nucleus
(Wang et al, 2012) during the interphase from G1 to G2 phase
(Goto et al, 2012). It is also proposed that the phosphorylation
of CHK1 by CdK1 is at a site distinct from that activated by
ATR (Ser286, Ser301) and triggers Crm-1-dependent nuclear
export of CHK1 to mediate cell cycle transition of G2/M phase
(Enomoto et al, 2009). Others propose that activation of CHK1 by
Table 2. ( Continued )
Nuclear CHK1 expression Cytoplasmic CHK1 expression
Biomarkers
Neg./low
expression
no. (%)
High expression
no. (%) P-value
Neg./low expression
no. (%)
Positive expression
no. (%) P-value
Cytokeratins (CK)
CK5
NEG 259 (74) 198 (78) 0213 87 (93) 702 (73) o0.0001
POS 208 (26) 56 (22) 7 (7) 256 (27)
CK17
NEG 519 (86) 180 (90) 0.074 74 (94) 625 (86)
POS 88 (15) 19 (10) 5 (6) 101 (14) 0.058
CK18
NEG 111 (16) 23 (9) 0.010 12 (11) 121 (14) 0.400
POS 603 (85) 232 (91) 96 (89) 739 (86)
Tumour suppressor, signalling and proliferation-associated proteins
p53
NEG 544 (71) 208 (74) 0.248 106 (85) 645 (80) o0.0001
POS 226 (29) 72 (26) 19 (15) 279 (30)
KI67
NEG 116 (50.9) 59 (56.7) o0.0001 61 (54) 335 (34) o0.0001
POS 112 (49.1) 45 (43.3) 53 (46) 659 (66)
Akt
NEG 131 (22) 51 (28) 0.137 36 (40) 146 (21) o0.0001
POS 458 (78) 134 (72) 55 (60) 537 (79)
PI3K
NEG 146 (22) 66 (28) 0.003 37 (34) 175 (23) 0.001
POS 510 (78) 164 72) 73 (66) 600 (77)
Abbreviations: AR¼ androgen; ATM¼Ataxia telangiectasia mutated; ATR¼Ataxia telangiectasia and Rad3-related protein; BARD1¼ BRCA1-associated RING domain protein 1; CHK1¼
checkpoint kinase1; CK¼ cytokeratin; EGFR¼ epidermal growth factor; FOXA1¼ Forkhead box protein A1; NEG¼ negative, PgR¼progesterone; PIAS¼protein inhibitor of activated STAT;
PI3K¼ phosphatidylinositide 3-kinases; POS¼positive; TN¼ triple negative. Bold indicates significant P-value (o0.05).
Table 3. The association between KPNA2 expression and CHK1 subcellular localisation
CHK1 nuclear and cytoplasmic expression Number of cases (%)
KPNA2 Nuc /cyto Nucþ /cyto Nuc /cytoþ Nucþ /cytoþ P-value
KPNA2 negative 37 (72) 19 (73) 225 (49) 94 (68) o0.0001
KPNA2 positive 14 (28) 7 (27) 233 (51) 45 (32)
Abbreviations: CHK1¼ checkpoint kinase1; cyto¼ cytoplasmic; KPNA2¼ karyopherin alpha 2; Nuc¼ nuclear.
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Figure 2. pCHK1 subcellular localisation and outcome. Kaplan–Meier curve of nuclear (A) and cytoplasmic (B) pCHK1 expression in the whole
series of breast cancer patients with respect to BCSS for 5 years. Kaplan–Meier curve of nuclear (C) and cytoplasmic (D) pCHK1 expression in the
whole series of breast cancer patients with respect to BCSS for 15 years.
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Figure 3. pCHK1 and outcome with respect to adjuvant chemotherapy. Kaplan–Meier curve of nuclear pCHK1 in patients who did not receive
chemotherapy (A) or who received chemotherapy (B) with respect to BCSS at 15 years. Panels C, D represent Kaplan–Meier curve of cytoplasmic
pCHK1 in patients without chemotherapy (C) or in patient who received chemotherapy (D) with respect to BCSS for 15 years.
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ATR-dependent phosphorylation leads to rapid release of CHK1
from the nucleus to the cytoplasm (Zhang et al, 2005; Smits et al,
2006). It is also suggested that the phosphorylated form of CHK1 is
able to regulate checkpoint protein events both in the cytoplasm
and in the nucleus (Sørensen et al, 2005); for example, in the
nucleus there will be activation of Rad51. It was also reported
that mono- or diubiquitination promotes CHK1 nuclear exclusion
(Kramer et al, 2004; Dunaway et al, 2005; Loffler et al, 2007;
Wilsker et al, 2008). These results together with our findings
suggest that subcellular localisation of CHK1 is important and is
associated with different functions.
Regarding outcome, tumours with nuclear and cytoplasmic
pCHK1 expression are associated with longer and shorter survival,
respectively; however, this effect was not independent of other
prognostic markers assessed in this study in the whole series.
Importantly, the association between nuclear pCHK1 and
outcome was different in patients who received or did not receive
CMF chemotherapy in our series. This effect was also different
between ER-positive and ER-negative tumours, a finding that may
reflect the known difference in DDR status between ER-positive
and ER-negative BC. In the whole series, an association between
positive nuclear pCHK1 expression and longer survival was found
in the subgroup of patients who did not receive chemotherapy;
however, no such effect was seen in patients who received
chemotherapy. The same findings were maintained in the ER-
positive subgroup. However, in the ER-negative and triple-negative
cohorts, the opposite was identified; no association with outcome
was observed in chemotherapy-naive patients, whereas in those
patients who received CMF chemotherapy tumour cell expression
of nuclear pCHK1 was associated with shorter survival. The
association between pCHK1 expression and chemotherapy
response in relation to outcome is a reflection of tumour response
and was significant in the whole patient series and in the clinically
important ER-negative subgroup. These results may indicate that,
although positive nuclear pCHK1 is a marker associated with
markers of good prognosis and with longer survival in chemo-
therapy-naive patients, in chemotherapy-treated patients it is
associated with reduced survival that may reflect chemoresistance
particularly in the ER-negative tumours. These results support the
findings of previous studies where an association between
chemoresistance and CHK1 expression has been observed
(Bartek and Lukas, 2003; Kastan and Bartek, 2004; Zhou and
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Figure 4. pCHK1 and outcome with respect to adjuvant chemotherapy in the molecular classes. Panels A, B represent Kaplan–Meier curve of
nuclear pCHK1 in patients who received chemotherapy in ERþ cases with respect to BCSS at 15 years, whereas C, D for ER—cases. Panel E
represents Kaplan–Meier curve of nuclear pCHK1 in triple negative patients who received chemotherapy. Abbreviations: Chemo¼ chemotherapy;
TN¼ triple-negative.
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Bartek, 2004; Tse et al, 2007; Verlinden et al, 2007; Dai and Grant,
2010; Merry et al, 2010; Carrassa and Damia, 2011; Ma et al, 2012).
However, in this study, the outcome of patients with tumours
expressing cytoplasmic pCHK1 was better when treated with CMF
chemotherapy, and further investigation of the interaction between
chemotherapy and CHK1 expression and its subcellular localisa-
tion is warranted ideally in a randomised clinical trial.
In conclusion, the results of this study emphasise that pCHK1 is
an important factor in BC, particularly with respect to DDR and
proliferation status, and its subcellular localisation has an impact
on the function of the protein. Nuclear pCHK1 was observed to be
associated with good prognostic markers and improved survival. In
contrast, cytoplasmic expression of pCHK1 is associated with
markers of poor prognosis and decreased survival. KPNA2 appears
to be involved in CHK1 subcellular localisation. CHK1 has a role
in the response of tumours to chemotherapy and subsequently
influences outcome. This effect is different between ER-positive
and -negative forms of BC. Further study of activating phosphor-
ylation of CHK1, such as phosphorylated ATR and downstream
targets such as phosphorylated CDC25A, CDC25B and CDC25C,
CDC25A, may help to understand the complex DDR biological
processes.
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